Sign In
Buy PBYI
$8.04
+0.380 (+4.96%)
At Close: Jun 23, 2026
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 08'th Aug 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported the issuance of inducement awards to three new hires, as required under Nasdaq Listing Rule 5635(c)(4).
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues
11:31am, Friday, 08'th Aug 2025
Puma Biotechnology tops second-quarter earnings and revenue estimates as rising Nerlynx sales drive growth.
Puma (PBYI) Q2 Revenue Rises 11%
12:52am, Friday, 08'th Aug 2025
Puma (PBYI) Q2 Revenue Rises 11%
Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript
08:53pm, Thursday, 07'th Aug 2025
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alan H. Auerbach - Founder, Chairman, President, CEO & Secretary Heather Blaber
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates
06:56pm, Thursday, 07'th Aug 2025
Puma Biotech (PBYI) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.05 per share a year ago.
Puma Biotechnology Reports Second Quarter Financial Results
04:05pm, Thursday, 07'th Aug 2025
LOS ANGELES--(BUSINESS WIRE)--On 8/7/2025, Puma Biotechnology issued 2Q-2025 earnings results and followed with a conference call to discuss quarterly and year-to-date results.
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results
04:15pm, Thursday, 24'th Jul 2025
LOS ANGELES--(BUSINESS WIRE)--On August 7, 2025, Puma Biotechnology will host a conference call/webcast to review its financial results for the second quarter of 2025.
Add These 4 Top-Ranked Liquid Stocks to Boost Portfolio Returns
09:36am, Tuesday, 15'th Jul 2025
INTU, NTGR, PBYI and DASH make the cut as top liquid stocks, with each boasting strong liquidity, growth attributes and operational efficiency.
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?
10:41am, Monday, 14'th Jul 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors
09:50am, Thursday, 10'th Jul 2025
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Puma Biotech (PBYI) could be a great choice. It is one of the several stocks that pa
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:03pm, Wednesday, 02'nd Jul 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement restricted stock units awarded to new hires in June 2025, as required by Nasdaq Listing Rule 5635(c)(4).
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?
10:41am, Friday, 27'th Jun 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Puma Biotechnology: Updated Timelines And A Resurgence In Sentiment
11:06am, Wednesday, 25'th Jun 2025
Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Neratinib's combination with trastuzumab deruxtecan shows intriguing signals, espec
Fast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain
09:50am, Tuesday, 24'th Jun 2025
Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks th
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
10:40am, Wednesday, 11'th Jun 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
